Chapter 3 . 1 Radiation dose of the novel Pgp tracer [ 11 C ] laniquidar

Resistance to current drug therapy is an important issue in the treatment of epilepsy. Inadequate access of central nervous system drugs to their targets in the brain may be caused by overexpression or overactivity of multidrug transporters, such as P-glycoprotein (P-gp), at the blood-brain barrier. Laniquidar, an inhibitor of P-gp, has been labeled with carbon-11 for the use in PET studies of P-gp expression in humans. Given potential interspecies diff erences in biodistribution, the purpose of this study was to ensure safe use of [C]laniquidar by determining the dosimetry of [C]laniquidar using whole body positron emission tomography (PET) studies.